Acorda Therapeutics (ACOR) Reports Q4 Loss of $0.67

Acorda Therapeutics (NASDAQ: ACOR) reported Q4 EPS of ($0.67), versus ($2.50) reported last year. Revenue for the quarter came in at $36.97 million versus the consensus estimate of $31.01 million.

For earnings history and earnings-related data on Acorda Therapeutics (ACOR) click here.

You May Also Be Interested In

• Tesla to launch Cybercab in Austin this month - report
• Infleqtion raises Q2 revenue to $13.5M after contract restatement
• The LGL Group (LGL) Misses Q2 EPS by 8c